/PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that.
Telaleaf Health Inc. (“Telaleaf” or the “Company”), a telemedicine company revolutionizing the delivery of cannabis care to patients,.
CARMAT announces the first human implant of its Aeson® artificial heart in Germany pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona s total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022 · Research programmes initiated in Type 1 Diabetes ( T1D ) and Amyotrophic Lateral Sclerosis ( ALS ) Syncona Ltd ( Syncona ) announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ( Quell ). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona s total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a 74 per cent fully diluted o